An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.

Trial Profile

An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Apr 2016 Planned number of patients changed from 54 to 56 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top